Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis

G. Ciprandi, A. Catrullo, M. Tosca, P. Cerqueti, C. Mondino, G. Passalacqua, G. W. Canonica

Research output: Contribution to journalArticle

Abstract

Mite allergy is characterized by a continuous allergen exposure. Persistent inflammation is therefore always detectable, and during symptomless periods as well. It has been reported that mite allergic patients also present a nonspecific hyperreactivity to different stimuli, including hyperosmolar solution. Since azelastine was previously demonstrated to be able to reduce allergic inflammation, the aim of the study was to investigate the effects of the drug on nonspecific conjunctival hyperreactivity in mite-allergic patients. Twenty children with mite allergy were studied. A hyperosmolar conjunctival challenge was performed before and after azelastine eye drops or placebo treatment for a period of 2 weeks. It was found that patients treated with azelastine eye drops showed a significant reduction in nonspecific conjunctival hyperreactivity compared to the placebo group (p = 0.018). It was concluded that azelastine eye drops are able to reduce the nonspecific hyperreactivity present in subjects with mite allergy.

Fingerprint

azelastine
Conjunctivitis
Ophthalmic Solutions
Mites
Glucose
Hypersensitivity
Placebos
Inflammation
Allergens

Keywords

  • Azelastine eye drops
  • Conjunctival challenge
  • Hyperosmolar solution
  • Minimal persistent inflammation
  • Mite allergy
  • Nonspecific hyperreactivity

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

@article{c24346a470d84dcb894256202ee91751,
title = "Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis",
abstract = "Mite allergy is characterized by a continuous allergen exposure. Persistent inflammation is therefore always detectable, and during symptomless periods as well. It has been reported that mite allergic patients also present a nonspecific hyperreactivity to different stimuli, including hyperosmolar solution. Since azelastine was previously demonstrated to be able to reduce allergic inflammation, the aim of the study was to investigate the effects of the drug on nonspecific conjunctival hyperreactivity in mite-allergic patients. Twenty children with mite allergy were studied. A hyperosmolar conjunctival challenge was performed before and after azelastine eye drops or placebo treatment for a period of 2 weeks. It was found that patients treated with azelastine eye drops showed a significant reduction in nonspecific conjunctival hyperreactivity compared to the placebo group (p = 0.018). It was concluded that azelastine eye drops are able to reduce the nonspecific hyperreactivity present in subjects with mite allergy.",
keywords = "Azelastine eye drops, Conjunctival challenge, Hyperosmolar solution, Minimal persistent inflammation, Mite allergy, Nonspecific hyperreactivity",
author = "G. Ciprandi and A. Catrullo and M. Tosca and P. Cerqueti and C. Mondino and G. Passalacqua and Canonica, {G. W.}",
year = "1999",
month = "1",
language = "English",
volume = "9",
pages = "35--38",
journal = "Journal of Investigational Allergology and Clinical Immunology",
issn = "1018-9068",
publisher = "Esmon",
number = "1",

}

TY - JOUR

T1 - Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis

AU - Ciprandi, G.

AU - Catrullo, A.

AU - Tosca, M.

AU - Cerqueti, P.

AU - Mondino, C.

AU - Passalacqua, G.

AU - Canonica, G. W.

PY - 1999/1

Y1 - 1999/1

N2 - Mite allergy is characterized by a continuous allergen exposure. Persistent inflammation is therefore always detectable, and during symptomless periods as well. It has been reported that mite allergic patients also present a nonspecific hyperreactivity to different stimuli, including hyperosmolar solution. Since azelastine was previously demonstrated to be able to reduce allergic inflammation, the aim of the study was to investigate the effects of the drug on nonspecific conjunctival hyperreactivity in mite-allergic patients. Twenty children with mite allergy were studied. A hyperosmolar conjunctival challenge was performed before and after azelastine eye drops or placebo treatment for a period of 2 weeks. It was found that patients treated with azelastine eye drops showed a significant reduction in nonspecific conjunctival hyperreactivity compared to the placebo group (p = 0.018). It was concluded that azelastine eye drops are able to reduce the nonspecific hyperreactivity present in subjects with mite allergy.

AB - Mite allergy is characterized by a continuous allergen exposure. Persistent inflammation is therefore always detectable, and during symptomless periods as well. It has been reported that mite allergic patients also present a nonspecific hyperreactivity to different stimuli, including hyperosmolar solution. Since azelastine was previously demonstrated to be able to reduce allergic inflammation, the aim of the study was to investigate the effects of the drug on nonspecific conjunctival hyperreactivity in mite-allergic patients. Twenty children with mite allergy were studied. A hyperosmolar conjunctival challenge was performed before and after azelastine eye drops or placebo treatment for a period of 2 weeks. It was found that patients treated with azelastine eye drops showed a significant reduction in nonspecific conjunctival hyperreactivity compared to the placebo group (p = 0.018). It was concluded that azelastine eye drops are able to reduce the nonspecific hyperreactivity present in subjects with mite allergy.

KW - Azelastine eye drops

KW - Conjunctival challenge

KW - Hyperosmolar solution

KW - Minimal persistent inflammation

KW - Mite allergy

KW - Nonspecific hyperreactivity

UR - http://www.scopus.com/inward/record.url?scp=0033059527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033059527&partnerID=8YFLogxK

M3 - Article

C2 - 10212855

AN - SCOPUS:0033059527

VL - 9

SP - 35

EP - 38

JO - Journal of Investigational Allergology and Clinical Immunology

JF - Journal of Investigational Allergology and Clinical Immunology

SN - 1018-9068

IS - 1

ER -